drugset / Trial / NCT00829088

Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

NCT00829088

Phase 1 Completed 6 enrolled AstraZeneca
NaSingle-groupOpen-label

Summary

The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.

Timeline

Start
2009-01
Primary completion
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2066 Small molecule Oral

Indications

No indication recorded.